雷莫芦单抗治疗 HER-2 阳性胃食管腺癌：克服曲妥珠单抗耐药的理由。
Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
机构信息
Department of Medical Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2L 4M1, Canada.
Department of Medical Oncology, University of Naples 'Luigi Vanvitelli', NA 80138, Italy.
出版信息
Future Oncol. 2018 Feb;14(3):223-228. doi: 10.2217/fon-2017-0434. Epub 2018 Jan 10.
AIM
Patients with advanced gastric cancer have a relatively poor prognosis with few therapeutic alternatives beyond first-line therapy. The purpose of this manuscript is to highlight the potential for prolonged responses in patients with HER-2-positive disease. Patients, materials & methods: We analyzed the data of patients diagnosed with HER-2-positive-advanced gastric cancer who progressed on trastuzumab-based combination therapy and subsequently received second-line therapy consisting of ramucirumab in combination with paclitaxel.
RESULTS
Most patients had a stable disease after ramucirumab-based therapy (50%, 5/10), median duration to disease control was 8 months.
CONCLUSION
The prolonged duration of response that we observed indicates that an interaction between the EGF pathway and the angiogenesis pathway requires further clinical investigations.
目的
晚期胃癌患者的预后相对较差，一线治疗以外的治疗选择有限。本文旨在强调 HER-2 阳性疾病患者可能获得长期缓解。
患者、材料和方法：我们分析了接受曲妥珠单抗为基础的联合治疗后进展，随后接受雷莫芦单抗联合紫杉醇二线治疗的 HER-2 阳性晚期胃癌患者的数据。
结果
大多数患者在接受雷莫芦单抗治疗后疾病稳定（50%，5/10），疾病控制的中位时间为 8 个月。
结论
我们观察到的反应持续时间延长表明，EGF 通路和血管生成通路之间的相互作用需要进一步的临床研究。
Zotero 插件